Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan

British Journal of Cancer

Volumn 103, Issue 4, 2010, Pages 469-474

  Okusaka, T ^a   Nakachi, K ^b   Fukutomi, A ^c   Mizuno, N ^d   Ohkawa, S ^e   Funakoshi, A ^f   Nagino, M ^g   Kondo, S ^h   Nagaoka, S ⁱ   Funai, J ⁱ   Koshiji, M ⁱ   Nambu, Y ⁱ   Furuse, J ^j   Miyazaki, M ^k   Nimura, Y ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ ELI LILLY AND COMPANY   (United States)

^j KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

biliary tract cancer; cisplatin; combination chemotherapy; gemcitabine

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; TEGAFUR; UFT; URACIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT CANCER; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77955517750     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605779     Document Type: Article

References (23)

1. Aljiffry M, Walsh MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 15: 4240-4262
2. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530
3. Charoentum C, Thongprasert S, Chewaskulyong B, Munprakan S (2007) Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol 13: 2852-2854
4. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, Awasthy BS (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90: 1516-1520
5. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896-902
6. Goodman MT, Yamamoto J (2007) Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002. Cancer Causes Control 18: 415-422
7. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B (2006) Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24: 1152-1160
8. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K (2006) A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106: 1339-1346
9. Lee J, Kim TY, Lee MA, Ahn MJ, Kim HK, Lim HY, Lee NS, Park BJ, Kim JS (2008) Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 61: 47-52
10. Matsuda T, Marugame T (2007) International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII Jpn J Clin Oncol 37: 74-75
11. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS (2008) Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 53: 564-570
12. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57: 647-653
13. Park BK, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY (2006) Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 21: 999-1003
14. Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH (2009) Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 115: 4148-4155
15. Pasetto LM, D'Andrea MR, Falci C, Monfardini S (2007) Gemcitabine in advanced biliary tract cancers. Crit Rev in Oncol Hematol 61: 230-242
16. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(4 Suppl 11): 72-79
17. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20: 146-159
18. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381
19. Thongprasert S, Napapan S, Charoentum C, Moonprakan S (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16: 279-281
20. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J (2009a) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer 101: 621-627
21. Valle JW, Wasan HS, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton M, Bridgewater JA (2009b) Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 27: 15s (Suppl; abstract 4503)(Recently the results of this study were published as follows:
22. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281)
23. Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE (2009) Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 101: 1846-1852